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Abstract
Background: The purpose of this work was to characterize the expression of drug and nutrient carriers along
the anterior-posterior and crypt-villus axes of the intestinal epithelium and to study the validity of utilizing whole
gut tissue rather than purified epithelial cells to examine regional variations in gene expression.
Results: We have characterized the mRNA expression profiles of 76 % of all currently known transporters along
the anterior-posterior axis of the gut. This is the first study to describe the expression profiles of the majority of
all known transporters in the intestine. The expression profiles of transporters, as defined according to the Gene
Ontology consortium, were measured in whole tissue of the murine duodenum, jejunum, ileum and colon using
high-density microarrays. For nine transporters (Abca1, Abcc1, Abcc3, Abcg8, Slc10a2, Slc28a2, Slc2a1, Slc34a2
and Slc5a8), the mRNA profiles were further measured by RT-PCR in laser micro-dissected crypt and villus
epithelial cells corresponding to the aforementioned intestinal regions. With respect to differentially regulated
transporters, the colon had a distinct expression profile from small intestinal segments. The majority (59 % for p
cutoff  ≤  0.05) of transporter mRNA levels were constant across the intestinal sections studied. For the
transporter subclass "carrier activity", which contains the majority of known carriers for biologically active
compounds, a significant change (p ≤  0.05) along the anterior-posterior axis was observed.
Conclusion: All nine transporters examined in laser-dissected material demonstrated good replication of the
region-specific profiles revealed by microarray. Furthermore, we suggest that the distribution characteristics of
Slc5a8 along the intestinal tract render it a suitable candidate carrier for monocarboxylate drugs in the posterior
portion of the intestine. Our findings also predict that there is a significant difference in the absorption of carrier-
mediated compounds in the different intestinal segments. The most pronounced differences can be expected
between the adjoining segments ileum and colon, but the differences between the other adjoining segments are
not negligible. Finally, for the examined genes, profiles measured in whole intestinal tissue extracts are
representative of epithelial cell-only gene expression.
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Background
The absorption of biologically active compounds occurs
via passive transcellular, paracellular and carrier-mediated
transport mechanisms [1]. Analysis of the human genome
sequence suggested the presence of 406 genes encoding
ion channels and 883 genes encoding transporters [2].
Generally, these proteins establish the electrochemical
gradient across membranes and provide the means for
transporting electrolytes, amino acids, dipeptides, mon-
osaccharides, monocarboxylic acids, organic cations,
phosphates, nucleosides, and water-soluble vitamins
[3,4]. Frequently, transporters play a direct role in the
absorption of bioactive compounds from the intestinal
lumen. The bioavailability of some compounds can
depend significantly on carrier-mediated systems and,
thus, are sensitive to drug-drug and drug-food interac-
tions; however, these interactions tend to be more rele-
vant for bioactive molecules with low bioavailabilities [5].
The mRNA expression profiles of several functionally-
defined transporter families have already been measured
by real-time PCR [6,7]; yet, for a majority of biologically
active compounds it remains unknown which transport-
ers play a role in their absorption. Although the human
genome project has made the identification of most, if not
all, genes encoding transporters and ion channels possi-
ble, only a few studies have focused on intestinal trans-
porter expression using such genome-wide strategies [8-
11]. Therefore, insight into the expression profiles of
transporters along the intestinal tract enables a physiolog-
ically relevant assessment of their potential as drug- and
nutrient-carriers.
Even less is known about the expression of transporters
along the crypt-villus axis [12]. The extensive automated
literature data mining by Olsen et al. [12] revealed that
more transporters are known to be expressed in the villi
than in the crypts. Many transporters that are villus-spe-
cific have been implicated in absorption processes, such
as the oligopeptide transporter Slc15a1, facilitated glucose
transporter Slc2a10, and the sodium/glucose cotrans-
porter Slc5a1 [13]; whereas the crypt-specific, basolater-
ally expressed Na+/HCO3 co-transporter (Slc4a4) is
essential for intestinal anion secretion. Similarly, the
mulitrdrug resistance protein 1 (Abcc1), is crypt-specific,
basolaterally expressed and acts as a secretion pump for
various compounds [14,15]. On the other hand, P-glyco-
protein (Abcb1) is villus-specific, expressed on the apical
site and acts as well as a secretion pump for a variety of
drugs [5,16]. Although exceptions may be found, one can
assume that villus-specific transporters might be more
efficient as mediators of absorption as their surface avail-
ability is more extensive.
Messenger RNA levels may not always correlate with the
expression of encoded proteins [17]. Although use of pro-
teomic techniques increasingly serves to resolve discrep-
ancies between mRNA and protein levels, proteomics of
integral membrane proteins still remains a challenge [18].
Also, protein levels do not necessarily correlate with pro-
tein activity. Various studies indicate that genomic profil-
ing in combination with data mining of chemotoxicity
databases can be an efficient strategy to identify new puta-
tive drug carriers [19,20].
A first step in identifying genes relevant to drug absorp-
tion in the intestine is to obtain a molecular catalogue of
all expressed mRNAs. In this study, we used the high-den-
sity oligomer microarray by Affymetrix to measure the
mRNA expression levels of genes expressed in four intesti-
nal regions (duodenum, jejunum, ileum, and colon) in
the mouse. We identified all genes with transporter activ-
ity according to the Gene Ontology (GO) consortium sys-
tem that are represented on the microarrays. Then, we
examined specific transporter classes that are significantly
changed along the intestine and compared our findings to
publicly available human microarray data. Finally, the
mRNA expression of some selected transporters was meas-
ured along the crypt-villus axis using laser capture
microdissection.
Results
"Carriers" and in particular "symporters" and 
"antiporters" are significantly changed along the A-P axis. 
However, he transporter class as a whole is not
Even though 41 % of all genes on the microarray that
belong to the GO class "transporter activity" were differ-
entially expressed along the intestine (modified ANOVA,
p ≤  0.05), the class itself, however, was not found signifi-
cantly changed according to a Fisher's exact test (p ≤  0.05).
In 8 of the 17 transporter classes represented on the
microarrays (at depth 3 of the "transporter activity"
mother class, cf. Figure 1) more than 50 % of the genes
were differentially expressed along the intestine. But only
the classes "carriers", "electron" and "protein" were signif-
icantly altered (cf. Table 1) with "carriers" being the only
class whose subclasses showed significant changes. In par-
ticular, genes with "electrochemical potential-driven
transporter activity", and more specifically "antiporters"
and "symporters" were affected along the intestine.
Although the class "channel/pore" was not significantly
affected, it was the only transporter class (depth 3) besides
"carriers" that contained subclasses that varied signifi-
cantly, namely "chloride channel" (depth 7, 9 genes out of
13 were changed) and its subclass "voltage-gated chloride
channel" (depth 8, 7 genes out of 9 were changed).BMC Genomics 2005, 6:69 http://www.biomedcentral.com/1471-2164/6/69
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Expression profiles of transporters change along the whole 
intestinal tract, but most significantly between the ileum 
and colon
The number of significantly (p ≤  0.05) regulated genes
was not different when comparing the jejunum and ileum
and the ileum and colon (cf. Table 1). However,
comparisons of transporters revealed a trend that along
the A-P axis the differences between the adjoining
segments increased. Overall, this trend could also be
observed in the transporter subclasses except from the
"amine/polyamine", "ion transporter" and "protein"
classes. For instance, the biggest subclass in absolute num-
bers of differentially changed transporters was the class
"carrier". Along the intestine the difference between the
adjoining segments increases clearly from 35 genes (duo-
denum vs. jejunum) to 41 (jejunum vs. ileum) to 55
(ileum vs. colon). The changes, however, are only signifi-
cant (p ≤  0.05) for the comparisons duodenum vs. jeju-
num and ileum vs. colon. Interestingly, no significant
change was observed for the nodes of the jejunum vs.
ileum comparison indicating that relative to all genes
being differently expressed between the jejunum and the
ileum the number of differently regulated transporters
was not significantly higher.
Like the mother class "carriers", the number of differen-
tially regulated "symporters" and "antiporters" also
increased along the intestine. All changes were significant
for both types of porters except for "symporters" in the
comparison duodenum vs. jejunum (cf. Table 1).
A similar number of transporters are over-expressed in the 
small and in the large intestine, but generally transporters 
are expressed at higher levels in the small intestine than in 
the colon
In order to identify transporters which could be interest-
ing candidate carriers for bioactive compounds in the var-
ious segments, we examined expression profiles along the
intestinal tract. Comparing the expression levels of trans-
porter genes or genes involved in transporter activity in
Table 1: Classification according to the Gene Ontology system of genes differentially regulated along the intestine.
GO descriptiona Total (1-/G-F-Flag)b UGs on Chipsc DJb,d JIb,d ICb,d SI Cb,d
molecular function 2717 (1772/760/185) 6890 659 897 897 2055
 transporter activity 350 (244/75/31) 853 95 115 126 263
 amine/polyamine 18 (11/2/5) 35 8 7 11 14
 auxiliary transport protein 2 (2/0/0) 2 0 0 1 1
 carbohydrate 8 (5/1/2) 18 2 4 7 8
 carrier activity 124 (91/10/24) 262 35 41 55 98
 electrochemical potential-driven transporter 57 (43/9/5) 104 20 27 35 47
 porter 56 (42/9/5) 103 20 26 35 47
 antiporter 11 (10/0/1) 16 4 6 9 11
 cation\:cation antiporter 5 (5/0/0) 6 2 2 2 5
 symporter 30 (18/7/5) 51 10 12 16 26
 solute\:cation symporter 19 (10/5/4) 31 5 8 9 17
 solute\:Na symporter 17 (8/5/4) 26 4 7 8 14
 channel/pore class 64 (40/5/19) 211 15 19 22 47
 electron 36 (272/7) 65 10 12 16 29
 ion transporter 68 (49/5/14) 151 20 18 25 55
 Lipid 6 (3/2/1) 16 2 3 5 4
 neurotransmitter 8 (4/2/2) 12 2 3 5 7
 nb/ns./nt/nucleic acid 2 (2/0/0) 4 1 0 1 1
 Organic acid 22 (13/2/7) 43 8 9 11 16
 Oxygen 2 (2/0/0) 5 0 1 0 0
 Peptide 3 (3/0/0) 5 1 2 2 2
 permease 1 (1/0/0) 5 0 0 0 2
 Protein 78 (51/9/18) 163 18 17 13 56
 Vitamin/cofactor 3 (1/2/0) 7 1 2 2 2
 Water 1 (0/0/1) 2 0 0 1 1
aTransporter activity classes (depth 3) for which no changes were observed are not listed (number of UniGene clusters represented on the 
microarrays): amide (0), boron (0), drug (1), group translocator (0), lactone (0), nitric oxide (0), organic alcohol (0), peptidoglycan (0), 
siderochrome (0), toxin (0) and xenobiotic (0). bListed is the number of differentially regulated genes along the whole intestinal tract and more 
specifically between adjoining intestinal segments (p ≤  0.05). Grey cells indicate significant changes in the GO nodes (p ≤  0.05). cTotal number of 
UniGene clusters being represented on the three Mu74v2 GeneChips. dSum of all differentially expressed UniGene clusters, i.e., from type (1), (F) 
and (G).BMC Genomics 2005, 6:69 http://www.biomedcentral.com/1471-2164/6/69
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Selected branches of the classification system according to the Gene Ontology (GO) system Figure 1
Selected branches of the classification system according to the Gene Ontology (GO) system.BMC Genomics 2005, 6:69 http://www.biomedcentral.com/1471-2164/6/69
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the small intestine and the colon revealed that similar
numbers of genes were more highly expressed in either
the small or the large intestine. However, small intestinal
transporters were clearly more over-expressed (cf. Figure
2). The majority of differentially expressed transporters
are members of the solute carrier super family (Tables 2
and 3). The most pronounced change (fold changes >
300), however, was observed for fatty acid binding pro-
tein 1 (Fabp1). Among the transporters being more than
20 times over-expressed in the small intestine were the
neurotransmitter transporter Slc6a19, the sulfate trans-
porter pendrin-like protein 1 (Slc26a6), L-type amino
acid transporter 2 (Slc7a8), facilitated glucose transporter
2 (Slc2a2), the apolipoprotein C-II (Apoc2), the
D11Ertd18e, the retinol binding protein 2 (Rbp2), stero-
lin 1 and 2 (Abcg5 and Abcg8) (genes are listed in decreas-
ing order of the fold change). The Y(+)L-type amino acid
transporter 1 (Slc7a7), the concentrative nucleoside trans-
porter co-transporter (Slc28a3), the B(0,+)-type amino
acid transporter 1 (Slc7a9) were more than 10 times over-
expressed. In the colon, the most over-expressed trans-
porter was the neurotransmitter transporter Slc6a14
which was more than 200 times higher expressed in the
colon compared to the small intestine. Aquaporin 4
(Aqp4), serum amyloid A 3 (Saa3), the neurotransmitter
transporter Slc6a14, the facilitated glucose transporter 1
(Slc2a1) and aquaporin 8 (Aqp8) were more than 10
times over-expressed. The concentrative nucleoside trans-
porter 2 (Slc28a2, Cnt2) was the top five most over-
expressed transporter in the small intestine compared to
the colon, but its annotation quality was only classified as
"medium".
A-D: M (log2 of fold change) vs. A (log2 of absolute average intensity) plots of the pair-wise comparisons between intestinal  segments Figure 2
A-D: M (log2 of fold change) vs. A (log2 of absolute average intensity) plots of the pair-wise comparisons 
between intestinal segments. All genes are plotted in orange, and transporters for which both a significant difference was 
measured between the two segments of interest and had a "high" quality annotation are depicted in blue (p ≤  0.05). In black are 
the transporters highlighted which were measured in the crypts and the villi. Grey lines indicate thresholds for fold changes of 
four fold (M = ± 2) or five fold (M = ± 2.5), respectively.BMC Genomics 2005, 6:69 http://www.biomedcentral.com/1471-2164/6/69
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There are particular transporters that are clearly segment-
specific. However, most differentially regulated 
transporters are similarly expressed along the whole small 
intestine
A more detailed pair-wise comparison between the
adjoining segments indicated that the differences between
adjoining segments, regarding changes of expression lev-
els of transporters, increased along the intestine (cf. Figure
2, Tables 2 and 3). Most transporters that were differently
expressed between the small intestine and the colon were
similarly expressed along the length of the small intestine,
but differently changed between the ileum and the colon;
however, some transporters were clearly expressed in a
region-specific manner. Ferroportin 1 (Slc40a1) was
strongly over-expressed in the duodenum compared to
the other segments. Besides Slc40a1, the intestinal phos-
phate transporter (Slc34a2) had the most pronounced
fold change between jejunum and the duodenum. The
expression level of Slc34a2 increased along the small
intestine, but was again more lowly expressed in the colon
than in the ileum. Fabp1 is similarly expressed in the duo-
denum and the jejunum, but significantly (p ≤  0.05)
decreased in the ileum and even more in the colon.
Besides the Na+ dependent ileal bile acid transporter
(Slc10a2) and Slc34a2, the sodium transporter Slc5a8, a
tumor suppressor gene [21], was also more highly
Table 2: Differently regulated (p ≤  0.05) solute carriers with a minimum absolute fold change of four in pair-wise comparisons of 
adjoining intestinal segments. Bold cases indicate fold changes of five or higher (Means ± SDs, log2 scale, n = 3 or 9, respectively.).
Gene
Name
D > J D < J J > I J < I I > C I < C SI > C SI < C Literaturea Gene aliases References
Slc10a2 5.0 ± 1.2 Mouse and Human: Highly 
expressed in I
ASBT; ISBT [36, 37, 53]
Slc12a4 2.6 ± 0.5 2.9 ± 0.5 - KCC1; RBCKCC1
Slc13a1 2.8 ± 0.4 2.2 ± 0.5 Mouse: D/J ~ C < I; Human: 
only in kidney
Nas1; NaSi-1 [54, 55]
Slc14a1 2.2 ± 1.2 2.1 ± 1.2 Human: Expressed in C; 
Rat: expressed in C
UT-B [56, 57]
Slc17a6 2.2 ± 0.4 Rat: abundant in I DNPI, VGLUT2 [58]
Slc17a7 2.2 ± 0.4 -V g l u t 1
Slc19a3 3.8 ± 0.9 Human: D > J > C > I ThTr2 [59]
Slc1a1 2.4 ± 0.2 2.8 ± 0.2 Mouse: SI; rat: high in distal 
SI; human: intestine
EAAC1, EAAC2, EAAT3, 
MEAAC1
[60-62]
Slc20a1 2.8 ± 0.4 Mouse: Present in D Glvr-1, Glvr1 [63]
Slc25a22 2.8 ± 0.3 2.7 ± 0.3 Human: SI - [64]
Slc26a2 2.5 ± 0.3 Human: C > SI Dtd, ST-OB [65]
Slc26a6 5.4 ± 0.2 6.1 ± 0.3 Mouse: D, J, I > C; Human: 
D>C>J~I, SI > C
CFEX; Pat1 [66, 67]
Slc28a3 3.5 ± 1.2 3.5 ± 1.1 Human: D > J > I > C Cnt3 [68]
Slc2a1 3.9 ± 0.6 3.10 ± 0.3 Rat: Low expressed in SI; 
Human: expressed in colon 
carcinoma
Glut1; Glut-1 [69, 70]
Slc2a2 4.0 ± 0.4 2.6 ± 0.5 5.2 ± 0.8 Human: expressed in SI Glut2; Glut-2 [71]
Slc2a5 2.6 ± 0.4 3.2 ± 0.7 Mouse: expressed in SI; 
Human: expressed in J
Glut5; Slc5a [72, 73]
Slc34a2 4.0 ± 0.3 3.7 ± 0.2 4.9 ± 0.6 Mouse: expressed in SI and 
colon; Human: SI specific
Npt2b; NaPi-2b [35, 74]
Slc35a1 2.1 ± 0.2 2.7 ± 0.3 - -
Slc39a10 2.2 ± 0.3 --
Slc40a1 5.7 ± 0.3 2.5 ± 0.5 Mouse:high in D, not 
detected in I; Rat: expressed 
in D, C; Human: highly 
expressed in D
MTP; Ol5; Pcm; Dusg; Fpn1; 
MTP1; IREG1; Slc11a3; 
Slc39a1
[75-77]
Slc4a7 2.4 ± 0.2 2.5 ± 0.2 Human: expressed in SI and 
C
NBC3; NBCn1 [78]
Slc5a1 2.1 ± 0.1 2.7 ± 0.2 Mouse and Human: Specific 
for SI; Rat: possible 
expression in C
Sglt1 [79, 80]
Slc6a14 3.0 ± 1.9 6.0 ± 1.8 7.7 ± 0.7 Mouse: SI < C; Human: 
weak in C, absent in SI
ATB0plus; CATB0plus [81, 82]
Slc6a19 6.7 ± 0.6 6.8 ± 0.6 - B<0>AT1
Slc6a4 3.1 ± 0.1 3.1 ± 0.2 Mouse and human: Intestinal 
enterocytes
Htt; Sert; 5-HTT [83]
Slc7a7 3.6 ± 0.1 3.7 ± 0.2 Mouse: expressed in J, I; 
human: highly expressed in 
SI
my+lat1 [84, 85]
Slc7a8 2.1 ± 0.4 5.2 ± 0.7 5.7 ± 0.8 Mouse: expressed in SI LAT2 [86]
Slc7a9 3.8 ± 0.2 3.4 ± 0.2 Mouse and human: 
expressed in SI
CSNU3 [85]
Slco1b2 2.1 ± 1.1 - OATP2; Oatp4; lst-1; 
OATP-C; mlst-1; Slc21a6; 
Slc21a10
aD = Duodenum, J = Jejunum, I = Ileum, C = Colon, SI = Small intestine, - = No data found in the literatureBMC Genomics 2005, 6:69 http://www.biomedcentral.com/1471-2164/6/69
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expressed in the ileum compared to the jejunum, but sim-
ilarly expressed in the colon. On the other hand, Fabp1 is
the most highly expressed gene involved in transport
activity in the jejunum compared to the ileum. This is fol-
lowed by D11Ertd18e, which has been associated to the
sugar transporter super family based on its protein struc-
ture, and the facilitated glucose transporter member 2
(Slc2a2). Tables 2 and 3 show all transporters that were
differently regulated along the intestine and whose fold
changes were at least four-fold. Members of the ABC trans-
porter family have not been integrated in the tables as
they have been presented earlier in detail [10].
Most transporters are similarly expressed in mice and 
humans
In order to assess if the expression levels in the mouse are
a suitable estimator for the situation in humans our data
were compared to publicly available human microarray
data obtained with a custom-array. Overall, 20 % of all
annotated transporters in mouse were compared. Previ-
ous studies have shown that there is a good correlation
between data obtained with the Affymetrix platform and
the data obtained with this custom-array [22].
The majority of common orthologous transporters were
similarly expressed in the small intestine and the colon in
both mice and humans. Some genes, however, were no
less than four-fold up-regulated in at least one segment in
the mouse, but were not identified as being differently
regulated in humans except for low affinity Na-dependent
glucose transporter Slc5a2 (cf. Table 4). Other studies in
humans not using microarrays, however, suggest that
most of these genes have a similar expression profile in
mice and humans (Table 4) indicating that the fold
Table 3: Differently regulated (p ≤  0.05) non-SLC transporters with a minimum absolute fold change of four in any pair-wise 
comparison of adjoining intestinal segments. Bold cases indicate fold changes of five or higher (Means ± SDs, log2 scale, n = 3 or 9, 
respectively.).
Gene
Name
D>J D<J J>I J<I I>C I<C SI>C SI<C Literaturea Gene aliases References
Aldh9a1 2.4 ± 0.1 - ESTM40; TMABA-DH -
Apoc2 3.7 ± 0.5 2.5 ± 0.5 4.9 ± 0.6 Mouse: expressed in 
intestine; Rabbit: expressed 
in J, D; Human: expressed 
in J
-[ 8 7 - 8 9 ]
Aqp4 4.6 ± 0.8 4.3 ± 0.3 Mouse: present in SI in 
crypt cells, and C in 
epithelial surface cells; rat: 
SI, C
MIWC; mMIWC [90, 91]
Aqp5 2.9 ± 0.4 Rat: D only - [91]
Aqp8 4.8 ± 0.6 3.9 ± 0.4 Rat: SI and C - [91]
Atp2a3 2.1 ± 0.2 Human: C > SI Serca3; SERCA3b [92]
Atp7a 2.5 ± 0.5 4.0 ± 0.4 Human: Highly expressed 
in D
Mo; br; Blo; I14; blotchy; 
mottled; MNK; brindled
[93]
Chrna1 2.5 ± 0.4 - Acra; Achr-1 -
Chrne 2.0 ± 0.4 -A c r e -
Csng 2.0 ± 0.8 - Csn1s2a; Csn1s2b -
D11Ertd18e 4.7 ± 0.5 4.7 ± 1.0 - - -
Fabp1 5.2 ± 1.1 4.7 ± 1.1 8.3 ± 0.10 Mouse: D, proximal J>I, 
nothing in distal I; Human: 
highest in J, present in D, J, 
I, C
Fabpl; L-FABP [94]
Gfpt1 2.2 ± 0.4 2.4 ± 0.4 Mouse: expressed in SI and 
C; Human: C > SI
GFA; GFAT; Gfpt; GFAT1 [95, 96]
Gfpt2 2.1 ± 0.4 Human: SI and C very low 
expressed
- [96]
Gria1 2.2 ± 0.5 - Glr1; Glr-1; GluRA; Glur1; 
HIPA1; GluR-A; Glur-1
-
Grm3 2.4 ± 1.2 2.3 ± 1.2 - Gprc1c; mGluR3 -
Gsr 2.1 ± 0.3 -G r 1 ;  G r - 1 -
Kcna3 2.9 ± 0.6 2.0 ± 0.4 - Mk-3; Kv1.3; Kca1-3 -
Kcnk6 Mouse: C > SI Toss; Twik2; [97]
Kctd3 2.7 ± 1.2 2.7 ± 1.3 - NY-REN-45 -
Pkd2 2.4 ± 0.5 - - -
Pln 2.6 ± 0.5 - PLB -
Rbp2 2.8 ± 0.2 3.0 ± 0.3 4.7 ± 0.5 - Rbp-2; Crbp-2; CrbpII -
Rbp7 2.9 ± 0.3 2.7 ± 0.3 - CRBP-III -
Saa3 3.5 ± 0.6 4.0 ± 0.4 Mouse and Human: 
Expressed in SI and C
Saa-3 [98]
Stard5 2.9 ± 1.0 - D7Ertd152e -
Stx1b1 3.0 ± 1.2 - Stx1bl -
Trpm7 2.0 ± 1.0 -C H A K ;  P L I K  C H A K 1 ;  
Ltpr7; Ltrpc7;
-
Xdh 2.8 ± 0.3 Mouse: Strong in SI Xor; Xox1; Xox-1 [99]
aD = Duodenum, J = Jejunum, I = Ileum, C = Colon, SI = Small intestine, - = No data found in the literatureBMC Genomics 2005, 6:69 http://www.biomedcentral.com/1471-2164/6/69
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changes measured with the custom-array may to a certain
extent underestimate the true fold changes as shown ear-
lier [22].
The regulation of expression in whole intestinal tissues is a 
good indicator of the combined changes in epithelial crypt 
and villus cells
In order to assess whether the expression profiles of genes
in whole tissue reflect their expression in the epithelium,
we determined the expression profile of 12 genes in villus
and crypt cells using a combined laser micro-dissection
and RT-PCR approach. To validate this method we meas-
ured a marker for the villi (aminopeptidase N/Anpept),
for crypts in the small intestine, i.e., Paneth cells (defensin
related cryptdin 5/Defcr5) and crypts in the small intes-
tine and colon (caudal type homeo box 1/Cdx1).
Based on the expression levels of the three crypt/villus
markers, RNA obtained from laser dissection of the small
intestine seems to be highly enriched of region specific
material, i.e. villi samples do not contain a notable por-
tion of RNA originating from crypt cells (cf. Figure 3).
In order to assess the expression profiles of transporters
measured in whole intestinal tissue with microarrays, we
verified the mRNA levels of nine transporters (Abca1,
Abcc1, Abcc3, Abcg8, Slc10a2, Slc28a2, Slc2a1, Slc34a2
and Slc5a8) measured in the same RNA sample prepara-
tion by RT-PCR. The expression profiles measured with
microarray and RT-PCR had a good concordance. In gen-
eral, we observed that the profiles measured in the whole
tissue in the four segments reflected the average expres-
sion in the crypts and the villi.
Influence of the crypt-villus axis on the expression of 
transporters
To test if there is a relationship between the expression
profile along the intestine and along the crypt-villus axis,
we measured the expression of a subset of transporters in
laser-dissected material. We selected transporters which
were, based on microarray and RT-PCR results of the
whole tissue (cf. Table 5), not differentially expressed
along the intestine (Abca1, Abcc1, Abcc3), small intestine
specific (Abcg8), large intestine specific (Slc2a1), either
specific for the anterior small intestine (Slc28a2) or
posterior part of the whole intestine (Slc10a2, Slc34a2,
Slc5a8). All nine transporters examined in laser-dissected
material tended to conserve their tissue specificity along
the intestine (cf. Table 5, Figure 4). In other words, none
of the examined transporters was crypt-specific in one seg-
ment and villus-specific in another. Abcc1 and Slc2a1
were crypt-specific, whereas Slc34a2 villus-specific in at
least three segments. Abcg8 and Slc28a2 showed a villus-
specificity in the posterior part of the small intestine,
while Slc5a8 was only in the jejunum villus-specific and
Slc10a2 in the ileum.
Discussion
A crucial step in classifying genes into different molecular
functions is the use of a consistent and universal classifi-
cation system and a precise annotation of Affymetrix
probe sets. Therefore, we included the following features
in our analysis: i) Mapping of single probes to all
transcripts referred to in the UniGene database and attrib-
uting of annotation tags to each probe set, and ii) assign-
ing of flags to differentially regulated probe sets. Similar to
Chalifa-Caspi et al. [23], we have seen that the annotation
provided by Affymetrix (NetAffx) is not entirely accurate.
In the Affymetrix annotation a probe set is represented by
at most one UniGene cluster, while, conducting our own
mapping of Affymetrix probes onto UniGene, we
Table 4: Comparison of the relative expression levels of 
transporters in mice and humans. Only genes with at least one 
four-fold difference in pair-wise comparisons are shown
Gene 
Name
Humana Mousea
SI > C SI > C D > C J > C I > C
AQP5 x
SLC19A3 x
SLC26A6 xx x x
SLC28A3 xx x x
SLC2A2 xx x
SLC34A2 x
SLC37A4 x
SLC6A4 xx x
SLC7A7 xx x
SLC7A8 xx x x
SLC7A9 xx x
C > SI SI < C D < C J < C I < C
AQP4 xx x x
AQP8 xx x x
PKD2 x
SLC26A2b x
SLC10A2 x
SLC2A1 xx x x
SLC6A14 xx
SLC35A1 x
SLC40A1 x
SLC5A1c x
aPublished expression data are listed in tables 2 and 3. D = 
Duodenum, J = Jejunum, I = Ileum, C = Colon, SI = Small intestine, - = 
No data found in the literature. bAccording to Haila et al. [65] highly 
expressed in the human colon and low in the human small intestine. 
cAccording to Wright et al. [79] specific for human and mouse small 
intestine.BMC Genomics 2005, 6:69 http://www.biomedcentral.com/1471-2164/6/69
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observed that in a number of cases multiple UniGene
identifiers can be associated to a given probe set.
Based on our quality criteria, 48 % of all probe sets in the
murine genome were found to have a "high" quality
annotation on the microarrays used in this study. Thus,
selecting only "high" quality genes establishes a high
degree of confidence regarding the correct annotation of
probe sets.
We observed that the genes on the microarrays are not
represented by an equal number of probe sets. Hence, by
counting each probe set as a unit in the GO classification
system the way it is done by a majority of GO classifica-
tion programs such as MappFinder, OntoExpress and the
one provided by NetAffx, a bias may be introduced
[24,25]. Moreover, to our knowledge, none of the pro-
grams publicly available provides a confidence assess-
ment regarding the significantly regulated functional
Expression profiles of tissue-specific markers along the intestine Figure 3
Expression profiles of tissue-specific markers along the intestine. Blue, dash-dotted lines indicate the relative expres-
sion in the four intestinal segments (D, J, I, C) using microarrays (mean ± SD, n = 3 pools of 10 mice each). Black, continuous 
lines indicate the relative expression in the four intestinal segments in the crypts and villi using RT-PCR (mean ± SD, n = 5). 
Please note that connecting the black lines between crypts and villi are not logical connections and only for visual support.
Table 5: Segment and tissue specificity of transporters along the A-P and crypt-villus axis.
Transporter Segment-
Specificitya,M
Segment-
Specificitya,R
Tissue-Specificityb
Duodenum Jejunum Ileum Colon
Abca1 D=J=I=C J=I=C>D Crypts>Villi ND ND ND
Abcc1 D=J=I=C I=C>D=J Crypts>Villi Crypts>Villi Crypts>Villi ND
Abcc3 D=C>J=C>I=C I=C>D=J ND Crypts>Villi ND Crypts>Villi
Abcg8 J>I=D>C D=J=I>C ND Villi>Crypts Villi>Crypts ND
Slc10a2 I>C>D=J I>C>D=J ND ND Villi>Crypts ND
Slc28a2 D>J>I>C D=J=I>C ND Villi>Cryptsx Villi>Cryptsx ND
Slc2a1 C>D=J=I C>I>D=J ND Crypts>Villi Crypts>Villi Crypts>Villix
Slc34a2 I>C>J>D I>C=J>D ND Villi>Crypts Villi>Crypts Villi>Crypts
Slc5a8 C>I>D=J C=I>J>D ND Villi>Crypts ND ND
aExpression in the four intestinal segments (D, J, I, C) was measured in whole tissue using microarrays (M) and RT-PCR (R) (n = 3, p ≤  0.05). bTissue 
specificity was determined in laser dissected crypts and villi (n = 5, where p ≤  0.05 or if indicated with a superscript "*" p ≤  0.10). "ND" indicates 
that no significant difference in expression levels were measured between the crypt and villus epithelial cells.
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classes. Therefore, we developed a software, the so-called
ISREC Ontologizer (Io), that takes these factors into
account. The use of the flags (i.e., 1, F, G) provided with
the Io software permits such an assessment to be made. As
indicated in Figure 2, a significant portion of the results
have a flag "F" and were, therefore, considered ambigu-
ous. Some of these "flagged" results, based on UniGene
identifiers, could be due to the fact that some of the probe
sets are associated with the same UniGene cluster, but are
specific for different splice variants. However, we
observed a similar portion of ambiguous results (i.e., flag
"F") when doing the classification based on RefSeq iden-
tifiers and concluded that the ambiguity associated with
flagged genes may stem from probe design rather than the
differential expression of splice variants [26].
Some transporters are subject to post-translational modi-
fication and of course, one of the processing steps is trans-
location to the membrane. However, if one considers
mRNA to be representative of function, then the majority
of transporters can be expected to have similar activity
along the length of the intestine. In this regard, it is inter-
esting to note that a remarkable fraction of transporters
annotated with "carrier activity" are differentially regu-
lated along the A-P axis and could therefore significantly
influence the absorption of carrier-mediated bioactive
compounds. Our GO classification results indicate that, in
the context of the whole transcriptome, transporters do
not seem to be an especially dynamically regulated class,
which differs slightly to the conclusions made by Bates
and colleagues [9]. However, a direct comparison is
Expression profile of selected transporters along the intestine Figure 4
Expression profile of selected transporters along the intestine. Blue, dash-dotted lines indicate the relative expression 
in the four intestinal segments (D, J, I, C) using microarrays and brown dashed lines using RT-PCR (mean ± SD, n = 3 pools of 
10 mice each). The microarray results for the ABC family members are according to Mutch et al. [10]. Black, continuous lines 
indicate the relative expression in the villi (V) and crypts (C) as determined with laser dissected material and RT-PCR (mean ± 
SD, n = 5 individual mice). The black lines between crypts and villi are meant only for visual support.
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difficult to make, as the classification system used by Bates
et al. was not in accordance with the official GO
classification system, and this may underlie the different
biological conclusions made between the two studies.
Furthermore, more importantly, while that study
included only 4 % of all annotated transporters (6), this
study covers 76 % and, provides the first extensive over-
view of the genomic profiles of transporters in the intes-
tine. Similar to their study, the most pronounced
difference between adjoining regions was observed for the
ileum and the colon. Although, in general, the differen-
tially expressed transporters were more highly expressed
in the small intestine than in the colon, a surprisingly
high number of transporters were identified as being
more highly expressed in the colon than in the small
intestine [13]. Many of these transporters have been
described as highly expressed in the colon and involved in
the bi-directional transport of electrolytes and fluids,
which is the principal role of the colon [27]. However, the
majority of known drug and nutrient transporters or carri-
ers of bioactive compounds [28] are not differently
expressed between the small intestine and the colon.
The exploitation of transporters, which are highly
expressed in the colon or at similarly high levels as in the
small intestine is especially interesting for compounds
such as proteins and peptides, which are susceptible to the
high enzymatic activity present in the small intestine [29].
For example, Slc6a14, which transports neutral and
amino acids, might be an interesting candidate to be tar-
geted for carrier-mediated absorption. Generally, we
observed that most of the differentially regulated "carri-
ers" were not specifically over-expressed in any of the
three small intestinal segments, but overall more highly
expressed in the small intestine versus the colon. Thus, the
ileum, which contains smaller concentrations of pancre-
atic enzymes, could be a suitable tissue for compounds
that are sensitive to the activity of pancreatic enzymes.
Genes classified as having "carrier", "channel", "ion trans-
port" and "electron" and "neurotransmitter" activity are
most likely to have different expression levels between the
small intestine and colon and may, hence, play a more
significant role in the difference of active drug and nutri-
ent transport in these two anatomically distinct regions.
The expression profiles of the most strongly regulated
genes (i.e. absolute fold change of 4 between the seg-
ments) agreed with previous findings in mice (cf. Table 2).
Moreover, comparing transporter expression profiles in
mice and humans suggests that gut transcriptional profiles
obtained in mice are a valid estimator for the situation in
humans (Table 2 and Table 3).
There are several methods that can be used to characterize
the patterns of expression of a target gene. Traditionally,
labeled antisense specific probes have been widely used
for in situ hybridization to detect specific gene expression
in the intestinal epithelium [12,30]. This technique, how-
ever, is very labor-intensive when several candidates are
being tested. There are several techniques used to isolate
the epithelial layer from the lamina propria of the intes-
tine [31]. These methods use mechanical procedures and
detergents and/or EDTA to detach the epithelial layer.
Separation of crypts from villi epithelium can be achieved
following adequate separation procedures. However,
alterations of gene expression patterns depending on the
procedure as well as cross-contamination from different
tissue compartments are possible. Similarly, laser dissec-
tion microscopy has been developed to isolate single cells
[32]. A key step in this procedure is the selection of an ade-
quate fixation procedure that prevents RNA degradation
and preserves tissue histological integrity [33,34]. The
protocols used in the present study allows the assessment
of a minimally altered gene expression pattern that is con-
cordant with in situ hybridization experiments (M.
Rumbo unpublished data).
Within this context, our data suggest that the changes in
expression profiles measured in whole intestinal tissue
extracts are a suitable predictor for changes in epithelial
cell-only gene expression along the crypts and the villi;
however, it should be mentioned that all genes in our
comparison were already known to be expressed in the
epithelium. This good correlation could reflect the fact
that these genes are solely expressed in the epithelium or
that the epithelium contributes much more to the isolated
RNA than underlying layers of intestinal tissues and,
therefore dominates the genomic profile of the intestine.
Thus, for genes which are not solely expressed in the
epithelium the prediction based on measurements in
whole tissue might not be appropriate.
For some compounds, depending on the enzymatic stabil-
ity and solubilization characteristics, targeting of carriers
in distinct intestinal regions may selectively improve their
absorption and bioavailability. Thus, we analyzed the
expression profiles of known drug carriers along the intes-
tine. The major part of inorganic phosphorus (Pi) absorp-
tion from the small intestine occurs via a Na+-dependent
phosphate co-transporter, NaPi-IIb encoded by the gene
SLC34A2.  In vivo pharmacokinetic studies in rats have
indicated that foscarnet is transported across the entero-
cytes by the NaPi-IIb system and thus acts as a competitive
inhibitor of Pi  uptake [28]. Slc34a2 mRNA has been
shown to be expressed in the small intestine and the colon
[35], which is in accordance with our findings. Our stud-
ies further demonstrate that the expression significantly
increases along the A-P axis of the small intestine. As aBMC Genomics 2005, 6:69 http://www.biomedcentral.com/1471-2164/6/69
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consequence, the most efficient transport rate is expected
to arise in the ileum. In addition to the findings by
Hilfiker et al. [35] that Slc34a2 protein is expressed on the
apical membrane of mature enterocytes in the duodenum,
we observed that Slc34a2 mRNA is villus-specific along
the whole intestine except for the duodenum, reinforcing
the concept that transporters expressed in the villi epithe-
lium tend to be implicated more in absorptive processes.
Slc10a2 (ASBT), the primary carrier for Na+-dependent
bile salt uptake from the intestinal lumen by the ileum,
has been shown to be present in the brush-border mem-
brane of the terminal part of the ileum, but little is known
concerning its regulation along the intestine [36,37]. Var-
ious studies indicate that based on substrate examples
ASBT could be an important target for increasing the bio-
availability of various bile acid conjugates [28]. Our find-
ings confirm that Slc10a2 is especially highly expressed in
the ileum compared to proximal small intestinal regions;
however a comparable level was measured in the colon.
Interestingly, only in the ileum was Slc10a2 identified as
being villus-specific which could be an indication for its
specific role in the ileum.
The four members of the ABC families, Abcg8, Abca1,
Abcc1 and Abcc3, that we studied are known to act as
secretion pumps in the intestine [14,38,39]. In accord-
ance with earlier findings, Abcc3 expression increases
from the anterior to posterior part of the intestine [10,40].
On the other hand, our findings for Abcc3 did not indi-
cate an increase in mRNA expression from the crypts to
the villi as shown by Rost et al. [40] in rats. The mRNA
levels of Abcc1 along the crypt-villus axis were in accord-
ance with protein expression [14]. Generally, all four
members may play a significant role along the whole
small intestine as secretion pumps, whereas in the large
intestine, Abcg8 is not expected to be involved in the
secretion of compounds.
The transporter Slc28a2 is known to be involved in the
transport of nucleoside analogues such as some antiviral
compounds [41]. Nucleosides are relatively hydrophilic
molecules and their ability to be transported across cell
membranes is a critical determinant of their metabolism
[42]. Our data indicate that similar uptake rates can be
expected along the whole intestine when targeting this
carrier, as it is similarly expressed in the gut. On the other
hand, Slc2a1, which was significantly (p ≤  0.05) more
highly expressed in the colon, might be an appropriate
drug-carrier for compounds sensitive to pancreatic enzy-
matic degradation. It has to be noted though that the pro-
tein product of SLC2A1, GLUT1, is not detectable in
healthy human colon tissue, but only in colon cancer serv-
ing as a marker for poor prognosis [43,44]. Thus, it may
be an interesting drug-target/drug carrier in individuals
with colon cancers.
In contrast to GLUT1, SLC5A8 has been shown to be
highly expressed in the colon and to act as a tumor sup-
pressor gene. SLC5A8 is silenced by methylation in most
human colon tumors and reintroduction of this gene
leads to growth suppression [21]. Recent studies have
shown that SLC5A8 acts as a Na+-coupled transporter for
short chain fatty acids and monocarboxylates. Its trans-
port rate is strongly inhibited by various drugs such as ibu-
profen. We have shown for the first time that this gene is
expressed at similar levels in the distal regions of the gut
and seems to be preferentially expressed in the villi of the
small intestinal enterocytes. Summarizing, this Na+-cou-
pled transporter may be involved in the active transport of
known monocarboxylate drugs and serve as a valuable
drug-carrier for new drugs along the whole intestine.
Conclusion
In conclusion, we have characterized the mRNA expres-
sion profiles of 76 % of all currently known transporters
along the A-P axis of the gut. We have identified various
transporters that could serve as carriers for biologically
active compounds. The significant regional specificities
are likely to correspond to functional differences along
the length of the intestinal tract.
Finally, we have presented a comprehensive analysis of
regional variations in gene expression using whole gut tis-
sue that is sufficiently sensitive to provide a good assess-
ment of relative changes in regional gene expression in
epithelial cells; however, for the functionality of a given
transporter to be unequivocally determined, it will be crit-
ical to examine these epithelial cells in a cell-type specific
manner.
Methods
Animals and tissue handling
8 week-old male Hsd:ICR(CD-1) mice (Harlan, Nether-
lands) were provided by AMS Biotechnology (Lugano,
Switzerland). Thirty animals were divided into 3 pools.
The small intestine was extracted and divided into three
sections, where the first 2–3 cm after the stomach com-
prised the duodenum, the middle third the jejunum, and
the section before the ileo-ceco-colic junction comprised
the ileum. The colon was treated as a single intestinal
section.
Gene expression analysis using the murine Mu74v2 
GeneChips
Gene expression was measured as previously described
[10]. Briefly, total RNA extracts were provided by AMS
Biotechnology (Lugano, Switzerland) and RNA extraction
was performed identically for each pool of mice. RNA wasBMC Genomics 2005, 6:69 http://www.biomedcentral.com/1471-2164/6/69
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then re-purified, according to manufacturer's instructions
using the Nucleospin kit and contaminating genomic
DNA was removed by DNase1 treatment (Macherey-
Nagel AG, Oensingen, Switzerland). The quality and
quantity of RNA was determined using Agilent 2100 Bio-
analyser (Agilent Biotechnologies, Germany) (1.6 – 2.0
ratio for 28/18S and no significant amount of metabo-
lized products). For each murine gut tissue section, 5 µg
total RNA was used as the starting material for all individ-
ual samples. Labeling and fragmentation of cRNA, array
hybridization and scanning was performed according to
the protocol by Affymetrix. Fluorescence values from
scanning were analyzed with Affymetrix Gene Expression
Analysis Software (MAS 5.0). The complete data set is
publicly available at http://www.ncbi.nlm.nih.gov/geo/
through the accession number GSE849.
Laser dissection microscopy
The mRNA expression levels of selected transporters
(Abca1, Abcc1, Abcc3, Abcg8, Slc10a2, Slc28a2, Slc2a1,
Slc34a2 and Slc5a8) were measured in the crypts and villi
of the intestinal mucosa of five 8 week-old male
Hsd:ICR(CD-1) mice (Harlan, Netherlands). To assess the
performance of the micro-dissection, specific markers for
the crypt-villus axis were used (Anpept for villi, Cdx1 for
crypts and Defcr5 for crypts in the small intestine, namely
for Paneth cells) [45-48]. Immediately after sacrificing the
animals, the intestinal tract was removed and regions clas-
sified similar to the microarray tissue sample definitions
(cf. above). Sections of one cm length were cut and incu-
bated overnight in zinc fixative/sucrose 30% solution (5g
ZnCl2, 6g ZnAc2X2H2O, 0.1g CaAc2 in 1L of 0.1M Tris pH
7.4). Afterwards, they were embedded in OCT and frozen
by immersion in liquid nitrogen. 20 µm frozen sections
were cut and mounted on Leica membranes for dissecting
microscopy (Leica Microsystems, Wezlar, Germany), fixed
in 96 % ethanol for 30 s and colored for an equivalent
time with Mayer's hematoxylin solution. Membranes
were then rinsed in water for 1 minute, transferred for 10
s to 70 % ethanol, followed by 96 % ethanol and air dried.
Samples were processed using a laser dissecting micro-
scope (Leica Microsystems), coupled to a CCD camera.
Microdissected samples were collected in a tube cap
placed below the sample holder. Samples were collected
in 20 µL RNA lysis buffer. Total RNA was extracted using
the total RNA extraction Nucleospin II kit by Machery-
Nagel (Oensingen, Switzerland).
Real-time PCR (RT-PCR)
Reverse transcription (RT) was performed using Super-
script II (Gibco BRL). RT-PCR amplification was per-
formed using an ABI 5700 machine (Applied Biosystems,
Foster City, CA, USA) with the following thermal cycling
conditions: 2 min at 50°C, 10 min at 95°C, followed by
40 cycles of 95°C for 15 s and 60°C for 1 min. The quality
of all RNA samples were examined with the Agilent 2100
Bioanalyser (Agilent Biotechnologies, Germany). All sam-
ples were standardized to equal RNA concentration using
the RiboGreen RNA quantification kit (Molecular Probes,
Leiden, Netherlands) and measured in duplicates. Cycle
to cycle fluorescence emission was monitored and quanti-
fied using the GenAmp software provided by Applied Bio-
system. Data was normalized to Gapdh. Primer probes
were purchased from Applied Biosystems as Assays-on-
DemandSM (Applied Biosystems, Foster City, CA, USA)
Data analysis
GEA analysis and ANOVA of microarray data
Differential gene selection was determined using a Global
Error Assessment (GEA) method of analysis [49]. Genes
were considered as differentially regulated along the intes-
tinal tract if the p-value = 0.05. GEA assumes that the var-
iance of the absolute intensity of a given gene is a function
of the absolute intensity. Therefore, rather than treating
each gene on the microarray as a unique and unrelated
element, neighboring genes are binned into groups of 200
based on similar intensity signals and the mean squared
error is calculated for each bin. For tables 2 and 3 standard
deviations were calculated for each gene independently.
Analysis of RT-PCR data
A one-way ANOVA and pair-wise comparisons based on
Tukey's Honest Significant Difference method (p- values
as indicated in the figures and tables) were used to con-
firm differences in gene expression.
Annotation of probe sets and functional classification of 
genes
Whereas in NetAffx the UniGene identifier is determined
according to the probe set's representative sequence (i.e.,
the sequence used to design the probe set), we have inde-
pendently mapped the probes and attributed a quality tag
depending on the level of specificity [50]. In order to bet-
ter assess the significance of the findings it is necessary to
know if the different probe sets supposed to represent the
same transcript give the same result and if all the probes
in a probe set still represent one and the same transcript
according to the most recent reconstruction of the mouse
transcriptome. Therefore all probes of the Affymetrix
Mu74v2 GeneChip were mapped to the latest release of
UniGene clusters (Unigene build number 137, EST db,
HTC db, RefSeq db and mRNA db) by an in-house devel-
oped tag-matching software as described earlier [51].
On this basis, every probe set was assigned to one of four
probe set "quality classes". The top class "high", the only
one used in this work, requires that all the probes of the
same probe set have perfect sequence matches to at maxi-
mum two UniGene clusters, which was the case for 17625
probe sets, as defined elsewhere [51].BMC Genomics 2005, 6:69 http://www.biomedcentral.com/1471-2164/6/69
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Structure of classification program
Following the UniGene annotation, probe sets were asso-
ciated to the nodes they represent in the gene function tree
defined by the Gene Ontology (GO) project (http://
www.geneontology.org/, version of April 2004). For
probe sets mapping to two different UniGene clusters,
both clusters were considered for GO annotation.
A Java program called ISREC ontologizer (Io) was used to
efficiently browse and analyze the data. Io is a general pur-
pose Java program for classification of microarray results
according to an annotation system http://www.io.isb-
sib.ch/, which will be described in detail elsewhere. In
short, for a given list of (differentially regulated) probe
sets (features), Io shows their distribution over all GO
classes subdivided by classes of probe set quality and
evaluates the statistical significance of overrepresentation
of a GO class. This analysis can be done with the features
as individual entities or pooling in groups those that rep-
resent the same UniGene cluster to study the degree of
agreement between probe sets of the same cluster. In this
case, three counts are provided for each GO class: 1/F/G
("one"/"flagged"/"good"). The "One" counter is incre-
mented when the group to which a feature belongs
contains only that feature. For groups with more than one
feature, the "good" counter is incremented when all fea-
tures are present in the selected list of probe sets; other-
wise the "flagged" counter is incremented and indicates
an ambiguous experimental result.
Significant changes (p ≤  0.05) for each GO node were cal-
culated using a Fisher's exact test using the "1" or "F" or
"G" counts [52].
Comparison to human data
The mouse microarray data were compared to publicly
available microarray data (the data set is available at http:/
/www.ncbi.nlm.nih.gov/geo/ through the accession
number GSE1368) of the human small intestine and the
colon. For all "high quality" Affymetrix probe sets the cor-
responding human homologue genes were identified on
the human chip using the LocusLink identifier and the
Homologue mapping table ftp://ftp.ncbi.nih.gov/pub/
HomoloGene/. 224 orthologous transporters were identi-
fied as being in common between the two platforms.
Then, the relative fold changes observed in the mouse
were compared to the human data. In case of multiple
probes representing the same gene average expression val-
ues were used. In the case of the mouse data, relative fold
changes were calculated by comparing the expression lev-
els of each independent small intestinal segment to the
colon and the average of all three segments to the colon as
it was unclear which small intestinal segment was com-
pared to the colon in the human study. Only genes four
times or higher expressed in any segment compared to
another segment were considered in this comparison.
Authors' contributions
PA contributed to the design and coordination of the
study, carried out the laser dissection, comparison of
mouse and human microarray data and expression data in
the literature, participated in the development of the
ISREC ontologizer, was responsible for high level analysis
of microarray data and drafted the manuscript. TS partici-
pated in the development of the ISREC ontologizer and
the annotation of the probe sets, and implemented its
methods in the Java environment. DMM contributed to
the design of the study and participated in the editing of
the manuscript. MR set up the protocols for the LDM and
participated in the laser dissecting. VP was mainly respon-
sible for the annotation of the probe sets. RM performed
the global error assessment (GEA). MD participated in the
development of the ISREC ontologizer and participated in
the editing of the manuscript with respect to the statistical
methods. GW contributed to the design and planning of
the study, to the discussion and interpretation of results,
and to the writing of the manuscript. MR contributed to
the original conception, design and coordination of the
study. Further contribution was made to choosingproject
goals, experimental approaches, developing technical
resources towards advancement of the project, and finally
revising the manuscript prior to publication.
Note
In the following, the term "transporter" will refer to all
genes that are classified as genes with "transporter activ-
ity" according to the GO system. At the date of analysis the
ATP-binding cassette (ABC) transporters were not classi-
fied as genes with "transporter activity". Thus, this class
has not been integrated the GO analysis. However, in the
analysis of expression levels on a gene by gene basis the
ABC transporters have been integrated.
Please note that according to the official human HUGO
and mouse MGI system we will refer to human gene sym-
bols in upper case, and to mouse genes with a first letter
in capital and the subsequent ones in lower case.
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